The asymmetric unit of the title crystal structure is shown in the gure. Tables 1 and 2 contain details of the measurement method and a list of the atoms including atomic coordinates and displacement parameters.
. 
Source of material
The title compound was synthesized according to a reported procedure [6] . A mixture of 3,5-cyclohexanedione (10 mmol), 3,4,5-tri uorobenzaldehyde (10 mmol), malononitrile (10 mmol) and 4-(dimethylamino)pyridine (DMAP) (1 mmol) in ethanol (100 mL) was re uxed for 2-3 h and then cooled to room temperature. After ltering the precipitates, they were sequentially washed with ice-cooled water and ethanol and then dried under a vacuum.
Experimental details
Carbon-bound and Nitrogen-bound hydrogen atoms were placed in calculated positions and were included in the re nement in the riding model approximation, with U iso (H) set to 1.2Ueq(C).
Discussion
The growing interest in bioactive pyrans has led to an increasing demand for e cient syntheses of this class of heterocyclic compounds [1] . Several reports have found diverse applications for pyrans in medicine such as antitumor (including breast cancer and liver cancer), antiviral (including hepatitis B virus and in uenza virus), anti-in ammatory agents, or kinase inhibitors for the treatment of type 2 diabetes, hyperlipidemia, and obesity [2, 3] . Moreover, these compounds have remarkable potential in nanomedicine against malignant gliomas [4, 5] .
In the crystal structure of the title compound, the pyran ring is nearly planar whereas the ring containing the keto group is folded. The plane of the pyran ring is almost perpendicular to the plane of the tri orophenyl moiety. All bond lengths and angles are in the expected ranges.
